INVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-Market
SARASOTA, Fla., March 24, 2023 /PRNewswire/ — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture (“IVC”) procedure…
Comments Off on INVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-Market